Competing pathways of iron chelation: angiogenesis or anti-tumor activity: targeting different molecules to induce specific effects.
Le
Nghia T V
NT
Richardson
Des R
DR
D020533:Angiogenesis Inhibitors / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002453:Cell Cycle; D002455:Cell Division; D045744:Cell Line, Tumor; D015913:Chelation Therapy / Q000379:methods*; D004247:DNA / Q000378:metabolism; D003676:Deferoxamine / Q000378:metabolism; D006801:Humans; D051795:Hypoxia-Inducible Factor 1, alpha Subunit; D007501:Iron / Q000378:metabolism*; D007502:Iron Chelating Agents / Q000627:therapeutic use*; D009369:Neoplasms / Q000188:drug therapy*; D009389:Neovascularization, Pathologic; D018919:Neovascularization, Physiologic / Q000187:drug effects; D014157:Transcription Factors / Q000378:metabolism; D015854:Up-Regulation; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism
D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; C497442:HIF1A protein, human; D051795:Hypoxia-Inducible Factor 1, alpha Subunit; D007502:Iron Chelating Agents; D014157:Transcription Factors; D042461:Vascular Endothelial Growth Factor A; D004247:DNA; D007501:Iron; D003676:Deferoxamine